MaxCyte eBook Series: Exploring Electroporation
Exploring Electroporation eBook Series
Welcome to the "Exploring Electroporation" eBook series, a compelling journey into the heart of electroporation innovation brought to you by MaxCyte. Over two decades, MaxCyte has revolutionized cell engineering with our Flow Electroporation technology, setting new standards in transfection efficiency and cell viability. This series delves into the application of electroporation across four critical areas:
- Immunotherapy
- Genetic diseases
- iPSCs
- Screening
Discover how our cutting-edge ExPERT instruments are empowering researchers to pioneer treatments for the most challenging conditions. From concept to clinic, learn about the seamless workflow and scalability that Flow Electroporation offers, enabling rapid development pipelines that bring lifesaving therapies to patients faster.
Exploring Electroporation eBook 1: Immunotherapy
Exploring Electroporation eBook 2: Genetic Diseases
Exploring Electroporation eBook 3: iPSCs
Exploring Electroporation eBook 4: Screening
Coming soon
Exploring Electroporation eBook 1: Immunotherapy
This eBook highlights the use of electroporation in advancing cell therapy research, particularly in the context of immunotherapy for cancer treatment. The articles highlight the development of cGMP-compliant processes for non-viral T cell engineering and the improvement of treatment for patients with refractory cancer through CRISPR electroporation of T cells. The eBook also discusses the multiplexed engineering of NK cells to enhance their anti-tumor activity.
MaxCyte's electroporation technology enables the efficient delivery of various payloads into cells while maintaining cell viability and high yields. Additionally, the eBook touches on the manufacturing challenges with viral gene delivery, the safety concerns of viral vectors, and the potential of non-viral alternatives such as homology-directed repair (HDR) in conjunction with electroporation for site-specific delivery of transgenes.
Overall, the eBook underscores the progress and promise of electroporation and gene editing technologies in the field of immunotherapy, aiming to improve the safety, efficacy, and scalability of treatments for cancer patients. Key themes to the eBook:
- Electroporation and Immunotherapy: The eBook provides examples of how electroporation is utilized for immunotherapy. One such example is the electroporation of nS/MARt vectors, which provide long-term transgene expression in T cells. These vectors were delivered with high efficacy and viability into activated human CD3+ cells with the MaxCyte ExPERT GTx.
- Advancements in Genome Engineering: The scientific community has made significant strides in genome engineering to combat cancer. Researchers are employing more sophisticated strategies, including the multiplex targeting of cell surface receptors and the modulation of immune checkpoint inhibitors. These advancements herald a new era in cell engineering that aims to harness cell and gene therapy to fight cancer more effectively.
- MaxCyte Technology and Immunotherapy: MaxCyte’s electroporation technology is at the forefront of immunotherapy development. Electroporation ensures efficient delivery into cells of various payloads that are traditionally challenging to transfect. This non-viral method maintains the viability of these cells and enables the production of precisely engineered cells at high yields. MaxCyte's technology facilitates rapid and clinically scalable manufacturing processes, speeding effective and personalized immunotherapies to the clinic faster.
In conclusion, MaxCyte’s electroporation technology is a powerful tool for advancing immunotherapy. By enabling efficient gene delivery, electroporation facilitates the development of personalized therapies. Researchers are making significant strides in genome engineering, aiming to harness the potential of NK and T cells for cancer treatment. As scientists continue to develop cell and gene therapies with electroporation, we can expect further breakthroughs in immunotherapy, ultimately benefiting patients worldwide.
